A Phase II Study of DMP 115 to Assess Focal Liver Lesions
NCT ID: NCT00162058
Last Updated: 2011-08-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
80 participants
INTERVENTIONAL
2004-03-31
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
NCT03350165
Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
NCT03248882
Pilot Study of FFP104 Dose Escalation in PBC Subjects
NCT02193360
Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure
NCT00225901
An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging
NCT03335566
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Peflutren Lipid Microsphere Injectable Suspension
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Scheduled for liver biopsy within 30 days of study
* Scheduled for CT or MR within 30 days of study
Exclusion Criteria
* Subjects with right-to-left shunts
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lantheus Medical Imaging
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lantheus Medical Imaging
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward L.S. Leen, MD
Role: PRINCIPAL_INVESTIGATOR
Consultant Radiologist, Royal Infirmary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Glasgow, Scotland, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DMP 115-214
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.